4.70
0.86%
0.04
Handel nachbörslich:
4.72
0.02
+0.43%
Schlusskurs vom Vortag:
$4.66
Offen:
$4.7
24-Stunden-Volumen:
16,841
Relative Volume:
0.64
Marktkapitalisierung:
$6.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.35M
KGV:
-2.3383
EPS:
-2.01
Netto-Cashflow:
$-36.91M
1W Leistung:
-7.48%
1M Leistung:
-19.10%
6M Leistung:
-61.71%
1J Leistung:
-69.17%
Galecto Inc Stock (GLTO) Company Profile
Firmenname
Galecto Inc
Sektor
Branche
Telefon
45-70-70-52-10
Adresse
75 STATE STREET, BOSTON
Vergleichen Sie GLTO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
4.70 | 6.19M | 0 | -38.35M | -36.91M | -1.45 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-11-23 | Eingeleitet | BofA Securities | Buy |
2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Galecto Inc Aktie (GLTO) Neueste Nachrichten
Galecto stock plunges to 52-week low at $4.78 amid market challenges - Investing.com
Galecto stock hits 52-week low at $5.26 amid market challenges - Investing.com Nigeria
Galecto stock hits 52-week low at $5.26 amid market challenges By Investing.com - Investing.com South Africa
(GLTO) Trading Signals - Stock Traders Daily
Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia
GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India
Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy
(GLTO) Investment Report - Stock Traders Daily
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
(GLTO) On The My Stocks Page - Stock Traders Daily
Global Secondary Myelofibrosis Therapeutics Market Poised to Reach USD 2.74 Million by 2033 with a 6 - PharmiWeb.com
Galecto price target raised to $10 from $9 at Oppenheimer - Yahoo Finance
How to Take Advantage of moves in (GLTO) - Stock Traders Daily
Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer - MarketBeat
Galecto (NASDAQ:GLTO) Given New $10.00 Price Target at Oppenheimer - MarketBeat
Galecto adds Dr. Amy Wechsler to Board of Directors By Investing.com - Investing.com Canada
Galecto stock hits 52-week low at $6.61 amid market challenges - Investing.com Canada
Galecto adds Dr. Amy Wechsler to Board of Directors - Investing.com
Galecto Appoints Dr. Amy Wechsler to Board - TipRanks
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - The Manila Times
Galecto refocuses on cancer, acquires novel AML drug rights By Investing.com - Investing.com South Africa
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
Galecto stock hits 52-week low at $9.3 amid market challenges - Investing.com
Galecto stock hits 52-week low at $9.3 amid market challenges By Investing.com - Investing.com South Africa
Galecto Expands Oncology Portfolio with Strategic Acquisition - TipRanks
Galecto refocuses on cancer, acquires novel AML drug rights - Investing.com
Galecto Shares Slide on Leukemia Treatment Rights Acquisition - MarketWatch
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - The Manila Times
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Charter Communications Inc (CHTR-Q) QuotePress Release - The Globe and Mail
Robusta Coffee 10-T (RMK26) Quote - The Globe and Mail
Finanzdaten der Galecto Inc-Aktie (GLTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):